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Abstract
Objetives
The aim of this study was to identify CMV drug resistance mutations (DRM) in solid organ
transplant (SOT) recipients with suspected resistance comparing next-generation sequenc-
ing (NGS) with Sanger sequencing and assessing risk factors and the clinical impact of
resistance.
Methods
Using Sanger sequencing as the reference method, we prospectively assessed the ability of
NGS to detect CMV DRM in the UL97 and UL54 genes in a nationwide observational study
from September 2013 to August 2016.
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Results
Among 44 patients recruited, 14 DRM were detected by Sanger in 12 patients (27%) and 20
DRM were detected by NGS, in 16 (36%). NGS confirmed all the DRM detected by Sanger.
The additional six mutations detected by NGS were present in <20% of the sequenced pop-
ulation, being located in the UL97 gene and conferring high-level resistance to ganciclovir.
The presence of DRM by NGS was associated with lung transplantation (p = 0.050), the
administration of prophylaxis (p = 0.039), a higher mean time between transplantation and
suspicion of resistance (p = 0.038) and longer antiviral treatment duration before suspicion
(p = 0.024). However, the latter was the only factor independently associated with the pres-
ence of DRM by NGS in the multivariate analysis (OR 2.24, 95% CI 1.03 to 4.87).
Conclusions
NGS showed a higher yield than Sanger sequencing for detecting CMV resistance muta-
tions in SOT recipients. The presence of DRM detected by NGS was independently associ-
ated with longer antiviral treatment.
Introduction
Cytomegalovirus (CMV) infection is one of the most common complications in solid organ
transplant (SOT) patients. Currently, prophylaxis and preemptive treatments have decreased
the incidence of disease and death by CMV. However, mutations associated with resistance to
antivirals have become an important problem with a high associated morbidity and mortality
[1, 2].
In the transplant setting, the incidence of drug resistance mutations (DRM) is 5–12%
depending on the group of patients studied but may be higher than 20% in patients with sus-
pected DRM [3, 4].
Diagnostic laboratory testing should be performed whenever there is a criterion of suspi-
cion of resistance since suboptimal response to treatment may have other causes, and inade-
quate empiric changes in therapy may have adverse effects [5, 6]. Genotypic testing by Sanger
sequencing of the protein kinase gene (UL97) and DNA polymerase gene (UL54) is the usual
method for detecting drug resistance and is the basis of the selection of alternative therapy [7].
However, Sanger DNA sequencing is unable to detect and quantify subpopulations of viral
mutants of less than 20–30%, which may be crucial for selecting the most adequate therapy [8].
In the last years next generation sequencing (NGS) technologies have provided better
understanding of the complexity of variant populations, increasing the detection of subpopula-
tions of minority variants which have a prevalence of 1–3%. Nevertheless, to date, only a few
studies have evaluated CMV DRM using NGS and most of these studies were carried out in a
reduced number of patients [9– 12].
The present study was conducted within the context of the Group for the Study of Infection
in Transplantation (GESITRA), constituting one of its major lines of clinical research. The
nationwide network of Spanish hospitals participating in GESITRA has allowed the inclusion
of a wide variety of SOT recipients.
The aim of this study was to identify CMV drug resistance mutations in solid organ trans-
plant recipients with suspected resistance comparing NGS with Sanger sequencing and to
assessing risk factors and the clinical impact of resistance detected by NGS.
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Materials and methods
Settings and study population
We conducted a prospective observational study in nine hospitals included in the Spanish Net-
work for Research in Infectious Diseases (REIPI). Adult SOT patients with suspected DRM
were included in the study from September 2013 to August 2016. Resistance was suspected
when there was persistent or increasing CMV viral load despite� 2 weeks of appropriate anti-
viral treatment, or failure to have a significant improvement in clinical symptoms despite 2
weeks of full-dose antiviral therapy.[2,5,6]
The coordinating centre was the Hospital Clinic of Barcelona (Spain), which performed the
genotypic resistance testing as well as the data analysis. Patient treatment and follow-up were
conducted as per the protocol of each centre. All patients were initially treated with standard-
dose ganciclovir/valganciclovir (GCV/VGCV) (adjusted to renal function).
Monitoring of CMV viral load was based on local quantitative PCR-based assays. On the
suspicion of resistance, plasma samples were collected and frozen at -80˚C in the respective
hospital and sent in batches to the Microbiology Laboratory of the Hospital Clinic every 4
months. Thus, genotypic testing was not carried out in real time and all patients received
empiric treatment on the presence of suspected drug resistance.
Data at patient inclusion and during follow-up were registered in a clinical database at each
participating hospital. We reviewed medical histories in terms of viral response, rejection and
mortality at 3 months after suspicion of resistance.
The DRM detected by Sanger sequencing and NGS were also included in the database.
CMV infection and disease and acute cellular rejection were defined as described previously
[5, 6].
The study was endorsed by Group for the study of Infection in Transplantation (GESITRA)
and approved by the Ethical Committee of Hospital Clı´nic (Comite´ E´tico de Investigacio´n del
Hospital Clı´nic de Barcelona, CEIC), approval number HCB/2012/7598) as the reference com-
mittee for the all participating centres according to legal regulations in Spain.
Microbiological studies
In the coordinating laboratory, all samples were kept at -80˚C until processing. DNA extrac-
tion was performed in 500 μL of each plasma sample using the QIAsymphony system (Qiagen,
Hilden, Germany). CMV viral load was confirmed by CMV Real Time PCR (Nanogen
Advanced Diagnostics, Italy) according to the manufacturer’s instructions.
Subsequently, all samples were analysed by Sanger sequencing based on PCR amplification
of the CMV UL97 protein kinase gene (codons 400–670) in a single fragment and the UL54
DNA polymerase gene (codons 300–1000) in four fragments [3].
Afterwards, antiviral resistance NGS, using Ion Torrent PGM (Ion Personal Genome
Machine, Ion Torrent Life Technologies, South San Francisco, CA) was performed by flanking
both the UL97 and UL54 gene.
Primer and library design for NGS
To create DNA library, UL97 and UL54 primers and PCR conditions previously validated and
described by Sahoo MK et al were used [10].
After establishing the whole technique, pilot tests were performed in Ion Torrent PGM in
order to adjust the reproducibility of the technique. The test of reproducibility was carried out
in a total of 6 control samples which included: 2 samples without suspicion of resistance, 2
samples from QCMD with known DRMs, and 2 clinical samples with known DRMs tested by
Cytomegalovirus resistance in solid organ transplant recipients
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Sanger. The results were the same in two sequencing experiments. Each run had a pool of the 6
samples in 3 different libraries with the same DNA extract. [13]
The limit of detection to avoid false positive results was defined as 5% according to Sahoo
et al [10]
Sequencing and bioinformatic analyses
Forty-eight samples were sequenced in the Ion PGMTM 35 System for NGS. Quality assess-
ment of the FASTQ files was performed using FastQC–version 0.11.3 [14]. The resulting reads
were aligned to the human herpesvirus 5 strain Merlin reference genome (GenBank:
AY446894.2) using the BWA-MEM algorithm from BWA version 0.7.12 with default parame-
ters [15]. Alignments were sorted and indexed using Sambamba version 0.5.1 [16]. Duplicate
reads in sorted BAM files were identified and removed using Picard tools [17]. GATK base
quality score recalibration, insertion and delection (INDEL) realignment, and duplicate
removal were applied [18]. The discovery of single nucleotide polymorphisms (SNP) and
INDEL and genotyping were simultaneously performed across 12 samples to optimise this
method using standard filtering and variant quality score recalibration according to the GATK
Best Practices recommendations [19]. Genetic variant annotation and prediction of the effects
of variants on genes (such as amino acid changes) were done using snpEff [20]. To do this a
snpEff database was created using the information of the reference genome provided by Gen-
Bank. The resulting variant call format (VCF) files were post-processed with in-house R [21]
scripts using Bioconductor packages [22] to identify mutations by gene (i.e. UL54 and UL97)
in order to find the relative position of each mutation to the first position of the corresponding
gene and to filter mutations by missing calls by depth at a sample level (DP> = 5), by allele
depth (AD> = 5), and by poor quality calls (in which the percentile of minimum quality
accepted was 5%).
An average 247382 raw sequences per sample were obtained in the samples sequenced in
this study. After pipeline passing quality filters 142.078 reads were obtained per sample.The
mean coverage among the different amplicons was up to 2000X
Statistical analysis
A database was developed for the registry of the patients enrolled in Open Clinica 3.1 [GNU-
Lesser General Public License (GNU LGPL)].
Categorical variables are expressed as number and percentage of patients, and the median
(interquartile range [IQR]) is used for continuous variables with a non-normal distribution
and the mean (standard deviation [SD]) for those with a normal distribution. Categorical
variables were compared using the X2 test or the Fisher exact test. Continuous variables were
compared using the t test or the non-parametric Mann-Whitney test. Logistic regression
analyses were performed to identify variables associated with the presence of mutations. Var-
iables showing a significant result in the univariate analyses (p<0.05) were included in the
multivariate model (forward stepwise procedure). The Hosmer-Lemeshow goodness-of-fit
test was performed to assess the overall fit of the models [23]. The area under the receiver
operating characteristic (ROC) curve of the multivariate model to predict the presence of
mutations was calculated. Internal validation of the prediction model was conducted using
ordinary nonparametric bootstrapping with 1,000 bootstrap samples and bias-corrected,
accelerated 95% CIs [24] (S1 Text; S1 Table). The level of significance was set at 0.05
(2-tailed). All analyses were performed using IBM SPSS Statistics 22.0 (Armonk, New York,
USA).
Cytomegalovirus resistance in solid organ transplant recipients
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Results
During the study period, 48 adults who had undergone SOT and in whom CMV antiviral
resistance was suspected were included in the study. Four samples with a low CMV viral load
(< 1.000 copies/ml) were excluded from the analysis because neither Sanger sequencing nor
NGS could be carried out. Therefore, 44 patients were finally included. The baseline character-
istics of the study population are shown in Table 1.
Based on sequence analysis, 12 out of 44 (27%) patients showed CMV DRM by Sanger
sequencing, while 16 patients (36%) showed mutations by NGS (Table 2). All the 16 patients
had mutations in the UL97 gene and in addition, two patients had one mutation each in the
UL54 gene (D413N and P522A). The NGS identified six low abundance resistance mutations
that had not been reported by Sanger sequencing, since they were presented in <20% of the
viral population. Patients 8 and 16 showed two mutations in UL97 (C592G + M460V and
L595W + A594V respectively); in both cases. In these two patients, M460V and A594V,
Table 1. Comparison of the clinical characteristics of the study population at baseline.
Variables Overall Without Mutations With Mutations P value
(n = 44) (n = 28) (n = 16)
Age, mean (SD), years 52.5 (12.3) 54.1 (11.8) 49.8 (12.9) 0.26
Male sex, n (%) 32 (72.7) 22 (78.6) 10 (62.5) 0.30
Type of transplant, n (%) 0.24
Kidney 19 (43.2) 13 (46.4) 6 (37.5) 0.57
Liver 9 (20.5) 6 (21.4) 3 (18.8) >0�99
Heart 8 (18.2) 5 (17.9) 3 (18.8) >0.99
Lung 5 (11.4) 1 (3.6) 4 (25.0) 0.050
Kidney-pancreas 3 (6.8) 3 (10.7) 0 (0) 0.29
CMV serostatus, n (%)a 0.21
D+/R- 26 (61.9) 14 (53.8) 12 (75.0) 0.17
D+/R+ 13 (31.0) 10 (38.5) 3 (18.8) 0.30
D-/R+ 2 (4.8) 2 (7.7) 0 (0) 0.52
D-/R- 1 (2.4) 0 (0) 1 (6.3) 0.38
Induction therapy, n (%)
Basiliximab 21 (47.7) 16 (57.1) 5 (31.3) 0.098
Antithymocyte globulin 10 (22.7) 7 (25.0) 3 (18.8) 0.72
Initial maintenance therapy, n (%)b
Mycophenolate mofetil 36 (81.8) 23 (82.1) 13 (81.3) >0.99
Tacrolimus 35 (79.5) 24 (85.7) 11 (68.8) 0.25
Steroids 34 (77.3) 21 (75.0) 13 (81.3) 0.72
Cyclosporine 6 (13.6) 2 (7.1) 4 (25.0) 0.17
mTOR inhibitors 5 (11.4) 2 (7.1) 3 (18.8) 0.34
CMV prophylaxis, n (%) 24 (54.5) 12 (42.9) 12 (75.0) 0.039
�3 monthsc 18 (75.0) 10 (83.3) 8 (66.7) 0.64
�6 monthsc 6 (25.0) 2 (16.7) 4 (33.3)
Abbreviations: D-, negative donor; D+, positive donor; R-, negative recipient; R+, positive recipient; mTOR, mammalian target of rapamycin; n, number of cases; SD,
standard deviation
a CMV serostatus not specified in 2 patients
b May have had more than 1 initial maintenance
c Percentages calculated for patients with CMV prophylaxis
https://doi.org/10.1371/journal.pone.0219701.t001
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respectively, were only detected by NGS. These six mutations were reproducibly detected at
similar levels in two independent sequencing experiments. All the DRM identified by Sanger
were also identified by NGS. The lowest depth coverage obtained related to a resistance muta-
tion was 7% of the viral subpopulations.
The detection of mutations by NGS allowed the differentiation and comparison of the
patients with and without mutations (Tables 1 and 3). The presence of mutations was more
frequent in lung transplant recipients (p = 0.050) and in patients receiving prophylaxis (42.9%
vs. 75%, p = 0.039), regardless of its duration. The median time between transplantation and
suspicion of resistance was significantly longer in the group with DRM (211.5 days [87.5;
285.0] vs 108.5 days [43.5; 201.5] p = 0.038) as was the median treatment duration before sus-
picion of resistance (41.5 days [18.0; 75.5] vs 16.0 days [14.5; 22.5] (p = 0.024). At the time of
suspicion of resistance, 75% of patients without mutations were receiving therapy for asymp-
tomatic CMV replication and 50% of patients with DRM were receiving treatment for CMV
disease. CMV disease was diagnosed in 54.5% of patients. However, biopsy confirmation was
achieved in only 3 patients. All the patients were receiving standard GCV/VGCV doses at the
time of suspicion of resistance and in the absence of DRM study results the treatment was
empirically modified accordingly. In patients with a DRM, mTORi was added or changed
empirically (50%, p = 0.009). No statistically significant differences were observed between the
patients with and without mutations in relation to outcome at 3 months (Table 3).
Table 4 shows the clinical and virological data of the SOT recipients with known CMV
DRM. Of the variables associated with the presence of resistance mutations in the univariate
logistic regression analyses (S2 Text. S2 Table), treatment duration before suspicion of resis-
tance was the only factor independently associated with the presence of mutations in the mul-
tivariate analysis (log-transformed scale, OR 2.24, 95% CI 1.03 to 4.87). The area under the
ROC curve was 0.71 (95% CI 0.53 to 0.88) for the final model of mutations (S1 Fig).
Table 2. Detection of cytomegalovirus drug resistance mutations in the UL97 and UL54 genes by Sanger and next-generation sequencing.
PATIENT SANGER UL97 NGS (Coverage %) UL97 GCVa
RATIO
SANGER UL54 NGS Coverage % UL54 GCV/FOS/CDVa RATIO
1 L595S (15%) 9.2
2 M460V (19%) 8.3
3 A594V A594V (20%) 8.3
4 M460V M460V (29%) 8.3
5 M460V (19%) 8.3
6 L595S (14%) 9.2
7 L595S L595S (20%) 9.2
8 C592G C592G+M460V (26%/14%) 2.9/8.3
9 H520Q H520Q (30%) 10
10 M460V M460V (31%) 8.3 P522A P522A (22%) 3/1/4.1
11 L595S L595S (20%) 9.2
12 M460V M460V (26%) 8.3
13 M460I M460I (31%) 5 D413A D413A (24%) 6.5/0.8/11
14 A594P A594P (31%) 3
15 L595S L595S (23%) 9.2
16 L595W L595W+A594V (21%/7%) 5.1/8.3
aIC50 of mutant /IC50 of wild type. If IC50 >5 the resistance was considered of high grade while an IC50 <3 was considered as low-grade resistance.
GCV: ganciclovir, FOS: foscarnet, CDV:cidofovir
https://doi.org/10.1371/journal.pone.0219701.t002
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Discussion
Drug-resistant CMV infection is an important emerging problem in SOT recipients. However,
it may be underdiagnosed since mutation analysis is not routinely performed and the current
gold-standard Sanger sequencing method lacks sufficient sensitivity [1]. In the present study, a
NGS was compared with Sanger sequencing to identify mutations associated with resistance in
SOT patients with suspicion of resistance. Among the 44 patients recruited, 14 DRM were
detected by Sanger in 12 patients (27%) and 20 DRM were detected with NGS in 16 patients
(36%), respectively. NGS showed a higher sensitivity for the detection of mutations present in
<20% of the population sequenced which were not found by Sanger sequencing. Univariate
analysis of the clinical data revealed that the presence of DRM detected by NGS was associated
Table 3. Data at the onset and beyond the suspicion of resistance.
Variables Overall Without Mutations With Mutations P value
(n = 44) (n = 28) (n = 16)
Time interval between transplantation and suspicion, median (IQR), days 116.5 (60.0; 232.5) 108.5 (43.5; 201.5) 211.5 (87.5; 285.0) 0.038
Days of therapy before suspicion, median (IQR) 20.0 (15.0; 48.0) 16.0 (14.5; 22.5) 41.5 (18.0;75.5) 0.024
Treatment at the time of suspicion, n (%)
Preemptive treatment 28 (63.5) 21 (75.0) 7 (43.8) 0.038
Disease treatment 15 (34.1) 7 (25.0) 8 (50.0) 0.092
Prophylaxis 1 (2.3) 0 (0) 1 (6.3) 0.36
CMV viral load at the time of suspicion, median (IQR), copies/ml 11,304 (3,521; 64,105) 7,088 (2,415; 47,555) 36,236 (9,609; 65,247) 0.17
Symptoms at the time of suspicion, n (%)a 24 (54.5) 14 (50) 10 (62) 0.53
Viral syndromeb 13 (29.5) 10 (35.7) 3 (18.8) 0.31
Gastrointestinal diseasec 8 (18.2) 3 (10.7) 5 (31.3) 0.12
Pneumonitis 4 (9.1) 2 (7.1) 2 (12.5) 0.61
Retinitis 2 (4.5) 2 (7.1) 0 (0) 0.53
Hepatitis 1 (2.3) 1 (3.6) 0 (0) >0.99
Disseminated (>1 end organ) 1 (2.3) 0 (0) 1 (6.3) 0.36
Therapeutic strategy on suspicion, n (%)d
Increase GCV/VGC dose 15 (34.1) 10 (35.7) 5 (31.3) 0.764
Continue with standard GCV/VGCe dose 18 (40.9) 13 (46.4) 5 (31.3) 0.325
Decreased immunosuppression 12 (27.3) 6 (21.4) 6 37.5) 0.303
Switch or add mTOR inhibitors 11 (25.0) 3 (10.7) 8 (50.0) 0.009
Switch or add foscanet 8 (18.2) 3 (10.7) 5 (31.3) 0.12
Outcome (at 3 months)
Viral response
Total suppression of CMV replication 25 (56.8) 18 (64.3) 7 (43.8) 0.186
Incomplete suppression 19 (43.2) 10 (35.7) 9 (56.3) 0.156
Final outcomef
Graft rejection 5 (11.9) 3 (11.1) 2 (13.3) >0.99
Death 5 (11.9) 3 (11.1) 2 (13.3) >0.99
Abbreviations: IQR, interquartile range; mTOR, mammalian target of rapamycin; n, number of case
a May have had more than 1 symptom at the time of suspicion
b Viral syndrome: fever >38˚C(for at least 2 days in a 4 day period) associated with leucopenia, thrombocytopenia or increase in transaminases
c Gastrointestinal disease include: colitis, gastritis
d May have had more than 1 therapeutic strategy on suspicion
e Continue with standard prophylactic or treatment dose of GCV/VGC
fFinal outcome not specified in 2 patients
https://doi.org/10.1371/journal.pone.0219701.t003
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Table 4. Clinical and virological data in solid organ transplant recipients with cytomegalovirus resistance mutations.
Type of
Transplant
(CMV
serostatus)
Induction
therapy
Prophylaxis
(months)
Treatment on
suspicion
of resistancea
(Days)
Symptomatic on
suspicion of
resistance
UL97/UL54
DRM (Days
post-TX)
CMV
viral b
(copies/
ml)
Therapeutic
adaptation on
suspicion of
resistance
Virological and/
or clinical
outcome c
1 Kidney D+/R- ATG 3 M Disease VGC
900mg/12h (16)
Suspected colitis L595S (91) 4.180 GCV/VGC
increased mTORi
IS.
2 Kidney D+/R+ Basiliximab No Preemptive
treatment VGC
450mg/12h (15)
No M460V (68) 55.253 GCV/VGC
increased
CS.Total
resolution
3 Liver D+/R- No No Preemptive
treatment VGC
450mg/12h(15)
No A594V 63) 9.300 GCV/VGC
increased ISP
decreased
IS. Cell-mediated
rejection
4 Liver D+/R- No 3M Disease VGC
450mg/12h(15)
Viral syndromed,
Suspected colitis
M460V (203) 3.849 ISP decreased
Continue with
GCV/VGCV
CS.Total
resolution
5 Kidney D+/R+ Basiliximab 1M Disease VGC
450mg/12h(84)
Suspected gastritis M460V (235) 11.234 ISP decreased GCV/
VGC increased
mTORi
CS. Total
resolution
6 Kidney D+/R+ ATG No Disease VGC
450mg/12h(67)
Viral syndrome d
Suspected colitis
L595S (58) 114.167 GCV/VGC
increased
CS.Total
resolution
7 Heart D+/R- No 3M Disease VGC
100mg/12h (20)
Viral syndrome d L595S (350) 154.486 GCV/VGC
increased
IS
8 Kidney D+/R- ATG 3M Disease VGC
450mg/12h(61)
Suspected colitis C592G
+M460V
(102)
11.605 GCV/VGC
increased. mTORi
IS
9 Lung D+/R- No 12M Prophylaxis VGC
900mg/24h(38)
Confirmed
pneumonitis
H520Q (210) 33.772 ISP Decreased. FOS.
mTORi
CS.Total
resolution
10 Lung D+/R- No 12M Preemptive
treatment VGC
900mg/12h(96)
No M460V/
P522A (335)
68.494 ISP Decreased .FOS.
mTORi
IS
11 Lung D+/R- No 6M Preemptive
treatment VGC
900mg/12h(26)
No L595S (210) 38.700 ISP Decreased .FOS.
mTORi
CS.Total
resolution
12 Liver D+/R- No No Disease VGC
450mg/12h (45)
Confirmed
pneumonitis and
retinitis
M460V (340) 9.919 Continue with
GCV/VGCV.
mTORi
IS. Death
13 Lung D+/R- Basiliximab 12M Preemptive
treatment VGC
450mg/12h(231)
No M460I/
D413N (400)
62.000 GCV/VGC
increased.
Leflunomide
IS. Cell-mediated
rejection
14 Heart D+/R- Basiliximab 1M Preemptive
treatment VGC
450mg/12h(113)
Viral syndromed A594P (331) 59.879 Continue with
GCV/VGCV.
Maribavir
IS
15 Kidney D+/R- No 1M Disease VGC
450mg/12h(28)
Viral syndromec
Suspected colitis
L595S (112) 721.000 Switch to FOS IS. Death
16 Heart D+/R- Basiliximab 2M Preemptive
treatment VGC
900mg/12h(51)
Viral syndromed L595W
+A594V (84)
4.120 GCV/VGC
increased. FOS.
mTORi
CS.Total
resolution
CMV, cytomegalovirus; D, donor; R, recipient; TX, transplantation; GCV, ganciclovir; VGC, valganciclovir; FOS, foscarnet, CDV, cidofovir; ATG, antithymocyte
globulin; ISP, immunosuppression; IS, incomplete suppression; CS, total supression of CMV replication
aDrug/doses
bCMV viral load on suspicion of resistance
cVirological and clinical outcomes at 3 months
dPresence of fever >38˚C (for at least 2 days in a 4 day period) associated with leucopenia, thrombocytopenia or an increase in transaminases
https://doi.org/10.1371/journal.pone.0219701.t004
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with lung transplantation (p = 0.050), prophylactic treatment (p = 0.039), a higher mean time
between transplantation and suspicion of resistance (p = 0.038) and longer treatment duration
with GCV or VGCV before suspicion (p = 0.024). However, the latter was the only factor inde-
pendently associated with the presence of resistance mutations in the multivariate analysis.
Several aspects differentiate the present stydy from other similar studies in the field
reported to date, and these aspects can be summarized as follows:NGS was addressed to the
UL97 and UL54 genes, a relatively high number of patients, undergoing different solid organ
transplanted were studied, and associated risk factors were also evaluated.
The current gold standard for the genotypic detection of CMV drug resistance is Sanger
sequencing of the UL97 and UL54 genes. However, this technique cannot detect viral variants
that represent< 20% of the viral population [9, 10]. This lack of sensitivity can lead to contin-
ued administration of an antiviral to which resistance has developed and the subsequent expan-
sion of initially minority populations of resistant variants leading to the development of
treatment failure, increased morbidity and shortened graft survival. On the other hand, modifi-
cations in therapy following the identification of GCV resistance is associated with more rapid
viral clearance, further emphasising the importance of timely detection of resistance [7, 11, 12].
Recent studies have shown that NGS methods can provide new insights into viral diversity and
in the detection of low-abundance variants by the analysis of thousands of amplicons in a single
experiment [10, 25]. However, so far, only a few studies have focused on CMV-resistant
mutants. Most studies have included few patients and only some cover the UL97 gene [11, 12].
An exception to this is the study by Sahoo et al which evaluated DRM in both of the genes
involved using NGS in a considerable number of specimens [10]. However, this study did not
include an analysis of clinical factors. In our study, NGS identified six low abundance resistant
mutations that had not been reported by Sanger sequencing, thus suggesting that NGS is more
sensitive than Sanger since the use of high throughput sequencing allowed the detection of viral
subpopulations with a prevalence of 7%. All six mutations were located in the UL97 gene and
showed high-level resistance to GCV [26, 27]. In addition, two of these six DRM identified were
present as mixed mutations in two patients which may have important implications in patient
management. Therefore, studies with prospective monitoring of the abundance of such muta-
tions over time and an assessment of their association with virologic failure are necessary. UL54
DNA polymerase mutations are typically selected after prolonged GCV exposure and were
revealed in 2 lung transplant patients who had received a longer prophylaxis and preemptive
treatment [28, 29]. However, compared to Sanger sequencing NGS did not improve the detec-
tion sensitivity of DRM in the UL54 gene in concordance with the results of Sahoo et al [10].
In the present study longer treatment duration with antivirals before suspicion of resistance
was identified as a risk factor associated with DRM (p = 0.24)[1, 2], and is considered a major
factor in the selection and emergence of resistance. Lung transplantation showed the highest
incidence of DRM. It is important to note that 4 out of 5 lung transplant patients in our study
presented DRM and all had received lengthy preemptive treatment and antiviral prophylaxis
[29, 30]. Moreover, the presence of DRM was more frequent among transplant recipients who
had received prophylaxis (p = 0.039). Nonetheless, other factors may have also contributed to
this finding. The interdependence of host, virus and antiviral therapy is likely associated with
the development of DRM [31]. In fact, all the patients included in this study had one or more
known risk factors predisposing to DRM [1, 2]. Therefore, according to current consensus
guidelines genotypic testing confirmation should be done irrespective of any exclusion criteria
whenever antiviral resistance is suspected [5, 6], since resistance might otherwise be underesti-
mated similar to what has been described in previous reports [32]. In the present study, DRM
were found in unusual situations, such as during prophylaxis in one patient and in 3 patients
with CMV D+/R+ serostatus.
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Previous studies have reported antiviral resistance to be associated with increased attribut-
able morbidity and mortality [2]. This was not found in the present study, likely because
patients were only clinically followed during the first three months. Moreover, clinicians were
unaware of the presence of DRM in real time, and therefore, treatment was empirically modi-
fied. Thus, we were unable to evaluate the outcome of the patients according to Sanger or NGS
sequencing results. This should be addressed in future studies.
In our cohort, 64% of the patients suspected of having resistance to antivirals did not pres-
ent DRM. Therefore, as suggested previously other factors might contribute to treatment fail-
ure [33]. Emphasis should be given to prioritizing the optimization of host factors rather than
switching antiviral medications, thereby adjusting immunosuppressive therapy whenever pos-
sible. Additionally, blood GCV levels were not available and were not performed during the
clinical care of the patients studied, and thus, sub-therapeutic GCV levels may be a possible
cause of non-response to treatment in some patients. On the other hand, a recent study of
serial specimens received for genotypic testing showed that the first specimen tested negative
for DRM in more than half of the patients, although about two-thirds eventually became posi-
tive on repeated testing [4]. It could therefore be suggested that patients without DRM but
with suspected criteria of resistance should be closely monitored and new samples should be
studied for viral mutations.
Our study has limitations regarding the modest sample size and the lack of balance among
groups although it does reflect real life in a nation-wide cohort study. Our results should be
confirmed in larger and better balanced cohorts. Another limitation is that the analysis of
GCV resistance of the mutations was performed only when there was suspicion; Nonetheless,
these patients represented the group with the highest risk for antiviral resistant CMV.
In summary, the development of DRM may be a direct effect of a longer duration of antiviral
treatment, and thus, the implementation of effective CMV prevention strategies that minimise
drug exposure could lead to lower resistance rates. Although the clinical risk factors for drug
resistance have been relatively well defined, genotypic testing should be performed in all
patients with suspected criteria of resistance. Despite the lack of standardized protocols and the
complexity of the bioinformatics analysis for the use of NGS in routine clinical practice, the
results of this study suggests that NGS technology improves the genotypic diagnosis of DRM,
fundamentally in low-abundance variants and mixed populations allowing early detection of
the emergence of CMV-resistant strains and subsequent targeted adjustment of therapy.
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